Format

Send to

Choose Destination
Drug Discov Today. 2012 Dec;17(23-24):1282-8. doi: 10.1016/j.drudis.2012.07.003. Epub 2012 Jul 13.

Biosimilars and biobetters as tools for understanding and mitigating the immunogenicity of biotherapeutics.

Author information

1
Bristol-Myers Squibb, Bioanalytical Sciences, Princeton, NJ 08543, USA. maria.barbosa@bms.com

Abstract

In this article, we review key steps for the development of biosimilars and biobetters and related bioanalytical challenges, with a focus on how they are associated with immunogenicity. We analyze the factors that can impact antidrug antibody (ADA) responses and their correlations with preclinical and clinical outcomes to provide relevant insights and to answer questions, including what types of aggregate are immunogenic. We also address strategies for developing less-immunogenic biotherapeutics. Using interferon-β (IFN-β) as a case study, we explore the correlation between aggregation and immunogenicity. We dissect and integrate with clinical data the IFN-β preclinical immunogenicity and aggregation predictions and discuss the feasibility of developing an IFN-β with lower aggregation and/or immunogenicity.

PMID:
22796124
DOI:
10.1016/j.drudis.2012.07.003
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center